Latest News
AstraZeneca's Datroway recommended for EU approval as first-line treatment in metastatic triple-negative breast cancer
29 June 2026 - Biopharmaceutical company AstraZeneca PLC (LSE: AZN) (STO: AZN) (NYSE: AZN), announced on Monday that together with Daiichi Sankyo Company Limited, it has received a positive recommendation from the European Medicines Agency's Com...
Futura Medical appoints Market Performance Group as new US distribution partner for Eroxon
29 June 2026 - Consumer healthcare group Futura Medical plc (AIM: FUM) disclosed on Monday that it has terminated its US commercial agreement with Haleon plc (LSE: HLN) (NYSE: HLN) and appointed Market Performance Group as its new US distribution par...
genedrive partners with Thermo Fisher Scientific to develop high-throughput CYP2C19 test
29 June 2026 - Pharmacogenetic testing company genedrive plc (AIM: GDR) disclosed on Monday that it has entered a collaboration agreement with Thermo Fisher Scientific Inc (NYSE: TMO) to develop the Genedrive CYP2C19 HT Kit, a high-throughput in vitr...
Sobi receives US FDA's complete response letter for NASP (nanoencapsulated sirolimus plus pegadricase)
29 June 2026 - Sobi (STO: SOBI), a Sweden-based biopharmaceutical company, announced on Friday that the company received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) for the company's Biologics License Applicat...
Anivive Lifesciences' Laverdia receives FDA approval to treat canine lymphoma
29 June 2026 - Anivive Lifesciences, a California-based pharmaceutical company, announced on Friday that the US Food and Drug Administration (FDA) Center for Veterinary Medicine has granted full approval for Laverdia (verdinexor tablets), which the c...